Medtronic (MDT) said Monday its deep brain stimulation system for the treatment of Parkinson's disease symptoms has been approved by the Food and Drug Administration.
The company's BrainSense adaptive deep brain stimulation provides enhanced therapy personalization for symptom control that automatically adjusts, minimizing the need for patients to manually adjust stimulation. It uses a surgically implanted neurostimulator to transmit electrical signals to specific parts of the brain affected by neurological disorders.
The approval also includes Medtronic's BrainSense electrode identifier, which helps reduce patient time spent in clinic to program their deep brain stimulation settings. By using EI, clinicians can conduct an accurate and precise initial programming, 85% faster compared to traditional electrode selection, the company said.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。